Fig. 6: m-f-PBPK model predicted dose-dependent average (Css,avg) and maximum (Css,max) steady-state Δ9-THC and 11-OH-THC concentration in umbilical venous plasma (UVP) and fetal brain after daily maternal inhalation (10 mg) or oral (10 mg) Δ9-THC consumption at gestational week 15. | Nature Communications

Fig. 6: m-f-PBPK model predicted dose-dependent average (Css,avg) and maximum (Css,max) steady-state Δ9-THC and 11-OH-THC concentration in umbilical venous plasma (UVP) and fetal brain after daily maternal inhalation (10 mg) or oral (10 mg) Δ9-THC consumption at gestational week 15.

From: Quantification and prediction of human fetal (-)-Δ9-tetrahydrocannabinol/(±)-11-OH-Δ9-tetrahydrocannabinol exposure during pregnancy to inform fetal cannabis toxicity

Fig. 6

A/B At the inhalation Δ9-THC dose (10 mg; 32 µmol), the predicted UVP Css,avg & Cmax were 2.5 & 95 nM Δ9-THC and 2.1 & 13 nM 11-OH-THC and for the fetal brain these were 3.7 & 88 nM Δ9-THC and 7.0 & 40 nM 11-OH-THC, respectively. C/D At the typical oral Δ9-THC dose (10 mg; 32 µmol), the predicted UVP Css,avg & Css,max were 0.49 & 2.8 nM Δ9-THC and 2.6 & 12 nM 11-OH-THC. For the fetal brain these were 0.73 & 3.9 nM Δ9-THC and 8.9 & 38 nM 11-OH-THC, respectively. Insets show the 11-OH-THC predicted concentrations. Δ9-THC: 1 nM = 0.314 ng/mL; 11-OH-THC: 1 nM = 0.330 ng/mL. Source data are provided as a Source Data file.

Back to article page